Serious adverse events · children with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults and adolescents with scrub typhus
1 finding from 1 review
Serious adverse events (including mortality) · adults and children with chronic asthma
Macrolides showed no clear difference in serious adverse events (including mortality) Weighted mean study… compared with placebo (low certainty).
1 finding from 1 review
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found